Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib Treatment

NCT01863745 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastrointestinal Stromal Tumors

Interventions

DRUG: nilotinib

Sponsor

Novartis Pharmaceuticals